جستجوی استاد راهنمای دانشگاهی

James B. Kaper is a Professor and Chair of the Department of Microbiology & Immunology at the University of Maryland School of Medicine. He serves as Vice Dean for Academic Affairs and previously held leadership roles as Senior Associate Dean (2014–2019) and Chair (2007–present). His research focuses on the molecular pathogenesis of diarrheagenic Escherichia coli and Vibrio cholerae , including vaccine development and bacterial-host interactions. Education: BS (1973) and PhD (1979) in Microbiology from University of Maryland; Postdoc in Molecular Pathogenesis at University of Washington (1979–1981) Dr. Kaper’s work has led to the creation of live attenuated cholera vaccines, including CVD 103-HgR, the first licensed recombinant bacterial vaccine. His lab investigates bacterial genetics, intestinal colonization, and immune system activation, particularly TLR5 response to V. cholerae flagellin. He has authored 303 peer-reviewed articles and 68 book chapters. His research has been funded continuously by NIAID since 1982. Key publications include foundational work on V. cholerae vaccines (1984), genomic structure (1998), and quorum sensing in EHEC/EPEC (1999). His lab’s recent studies focus on phosphotyrosine proteomics (2013) and pathogenicity island regulation (2007). Scientific awards: Fellow, American Academy of Microbiology (1994); NIH Merit Award (2004); ASM DC White Award (2019) Editorial roles: Editor-in-Chief, EcoSal (2006–present); Associate Editor, International Journal of Medical Microbiology (2000–present) As an academic leader, Dr. Kaper has mentored over 60 graduate students and postdoctoral fellows. He holds multiple patents for cholera vaccines and E. coli diagnostics, including U.S. Patents 4,935,364; 5,399,494; and 6,204,004. His lab at UMSOM combines basic science with translational applications for enteric disease prevention.

• Microbiology
• Immunology
• Bacterial Vaccines
• +۵ مورد دیگر

Ning Zhang is an Assistant Professor in the Biology Department at James Madison University (JMU), joining in 2024. Her research focuses on enhancing crop resilience through molecular and biochemical studies of plant defense mechanisms against bacterial pathogens, alongside developing genome editing technologies for trait improvement. She holds a PhD in Horticulture and Crop Science from The Ohio State University (2016), an MS in Silviculture from Zhejiang Agriculture and Forestry University (2011), and a BS in Landscape Architecture from Shandong Agricultural University (2008). Research Interests: Dr. Zhang's lab investigates plant immunity pathways, CRISPR/Cas9 genome editing applications, and engineering crops for disease resistance. Her work integrates molecular biology, genetics, and biochemistry to tackle challenges posed by climate change and biotic/abiotic stresses. Recent Trends in Publications: Her articles concentrate on MAPK signaling pathways, NLR protein interactions, PP2C phosphatase regulation, and bacterial effector mechanisms in tomato and other crops. Key themes include immune system activation, pathogen recognition diversity, and transgenic plant development. Lab Information: The Zhang Lab at JMU is part of the Department of Biology, focusing on plant biotechnology solutions for agricultural sustainability. They collaborate on projects involving CRISPR-based gene editing and stress tolerance research.

• Plant Defense Mechanisms
• Genome Editing Technologies
• Crop Improvement
• +۳ مورد دیگر

Dr. Rebecca Pratt is a tenured Professor in the Department of Foundational Medical Studies at Oakland University William Beaumont School of Medicine (OUWB), where she has been a faculty member since January 2018. She previously held professorial roles at Michigan State University College of Osteopathic Medicine (MSUCOM), where she taught anatomy, embryology, neuroanatomy, physiology, and histology, and served as Associate Professor and Director of Histology at the West Virginia School of Osteopathic Medicine. She also held appointments at Grand Valley State University and completed postdoctoral training at Purdue University. Ph.D., Cell Biology and Oncology, Purdue University B.S., Zoology and Botany/Plant Pathology, Michigan State University Dr. Pratt's research focuses on the fascial system and its role in whole-body health, including fascial continuity, muscle attachment, somatic pain transmission, and biochemical communication. She integrates radiology into anatomy education and advocates for evidence-based medical curricula. Her work bridges clinical anatomy, histology, embryology, and physiology with modern educational practices. Her recent publications reflect a strong emphasis on fascial anatomy, medical education innovation, and the integration of imaging in teaching. Themes include plastination, generational learning trends, and fascia’s role in women's health and athletic performance, published in journals like Clinical Anatomy and Anatomical Sciences Education , as well as in Women and Men’s Health and NIKE magazines. Scientific awards and honors include: Basmajian Award (American Association of Anatomy) Keith and Marion Moore Award (AAA) Five consecutive Golden Apple Teaching Awards at MSUCOM Golden Apple Award at OUWB Dr. Pratt has served in major leadership roles, including President of the International Fascia Research Society, Board Member of the American Association of Anatomy (AAA) and the American Association of Clinical Anatomy (AACA), and Chair of multiple AAA committees. She is a Visiting Anatomy Professor at Weill Cornell and St. George’s University School of Medicine, and faculty advisor for the Docapellas at OUWB. She has been an invited speaker internationally and contributed to high-impact projects like the BodyWorlds Fascial Net Plastination Project. She actively serves on OUWB’s Admissions and Student Promotion and Retention Committees. Dr. Pratt leads and organizes major international initiatives, including the Women's Clinical Health Summit in Rio de Janeiro (2024) and the Fascia Research Congress in New Orleans (2025), fostering global collaboration in fascial science. Her lab and research team focus on fascial anatomy and medical education, working closely with institutions in Italy (University of Padova) and Germany (BodyWorlds project).

• Anatomy
• Fascial System Research
• Histology
• +۱۲ مورد دیگر

Andre Levchenko is the John C. Malone Professor of Biomedical Engineering at Yale University, with secondary appointments in the Department of Neurosurgery and affiliations with the Cancer Signaling Networks, Immunology, and the Yale Program in Neurodevelopment and Regeneration. His research focuses on systems biology, signal transduction, and cell-cell communication, utilizing microfluidics and computational modeling to study cancer progression, stem cell behavior, and neurological disorders. PhD, Columbia University MEng, Moscow Institute of Physics and Technology Levchenko's work explores how cells process dynamic signals to make critical decisions, particularly in glioblastoma migration, organoid development, and cardiovascular tissue engineering. His lab develops innovative microfluidic platforms and mathematical models to dissect multicellular communication and signaling networks. Recent publications highlight his contributions to understanding YAP-driven cancer invasion , NOTCH signaling in angiogenesis , and metabolic regulation of hypoxia responses . He has pioneered methods for organoid modeling and single-cell analysis , advancing precision in biological signaling studies. Scientific Awards : Computational Molecular Biology Post-Doctoral Fellowship (Burroughs Wellcome Fund) National Academies Keck Futures Conference Invitee Distinguished Guest Lecturer, University of Virginia American Asthma Foundation Early Excellence Award Fellow, American Institute for Medical and Biological Engineering Levchenko leads the Levchenko Lab at the Yale Systems Biology Institute, collaborating with institutions like Mayo Clinic and Yale Cancer Center. His research has received recognition in Faculty of 1000 and multiple journal highlights.

• Systems Biology
• Signal Transduction
• Cell Communication
• +۵ مورد دیگر

Kristian Helin is Chief Executive and President of The Institute of Cancer Research (ICR), London, and a Professor with affiliations at the University of Copenhagen and Memorial Sloan Kettering Cancer Center. He founded/directed the Biotech Research & Innovation Centre (BRIC), Centre for Epigenetics, and Danish Stem Cell Center. His research focuses on epigenetic regulation, cancer biology, and stem cell differentiation. Education: Ph.D. Molecular Biology, University of Copenhagen (1991) M.Sc. Chemical Engineering, Technical University of Denmark (1988) Research Interests: Helin's work deciphers molecular mechanisms in cancer, emphasizing epigenetic drivers (e.g., H3K4/H3K36 methylation), transcriptional control, and therapeutic targeting. His lab identified E2F transcription factors, linked epigenetic dysregulation to leukemia/lymphoma, and develops drugs targeting kinases/epigenetic enzymes. Research spans acute myeloid leukemia, B-cell lymphoma, and solid tumors using CRISPR screens and preclinical models. Publication Trends: Recent articles (2023-2025) focus on epigenetic therapy, chromatin remodeling, and kinase signaling in cancer. Key themes include targeting NSD1/KDM5C/RIOK2 enzymes, combination therapies (EZH2/DOT1L inhibitors), and metabolic regulation in leukemia. Studies bridge basic mechanisms (enhancer regulation, insulator accessibility) with translational applications. Awards: Anders Jahre Prize (2014), ERC Advanced Grant (2011), Novo Nordisk Prize (2008) Memberships: Academia Europaea, Royal Danish Academy, EMBO Leadership: Helin co-founded EpiTherapeutics (acquired by Gilead) and leads the Epigenetics and Cancer lab at ICR. His team investigates AML pathogenesis and chromatin complexes like HUSH/NURF. Grants include ERC funding and innovation prizes.

• Cancer biology
• Epigenetics
• Stem cells
• +۵ مورد دیگر

David John Procter is a Professor of Organic Chemistry and Head of the Department of Chemistry at the University of Manchester. His career includes academic roles at the University of Glasgow (Lecturer, Senior Lecturer) and a Readership at the University of Manchester, where he became a Professor in 2008. His research focuses on developing new synthetic methods, catalysis, and materials chemistry, with applications in drug discovery, biocatalysis, and organic electronics. Education: BSc Chemistry (University of Leeds, 1992), PhD (1995, supervised by Prof. Christopher Rayner). Postdoctoral work: Florida State University (Prof. Robert Holton, Taxol analog synthesis). Research interests include samarium diiodide-mediated reactions, metal-free coupling processes, and sustainable synthesis methods. He leads projects funded by EPSRC, Industry (30 grants), and international collaborations. Awards include the EPSRC Established Career Fellowship (2015–2020), Bader Prize (2014), and Young Heterocyclic Chemist Award (2015). Key contributions: Total synthesis of natural products (e.g., pleuromutilin), development of copper-catalyzed multicomponent couplings, and innovative methods for organic materials. His work aligns with UN Sustainable Development Goals related to affordable and clean energy and responsible consumption. Collaborations span academic and industrial partnerships in chemistry, physics, and biology. He supervises 60+ students and contributes to the Organic Materials Innovation Centre (OMIC). His group’s research is detailed at proctergroupresearch.com .

• Organic Synthesis
• Catalysis
• New Synthetic Methods
• +۵ مورد دیگر

Weiping Tang is a Professor of Pharmaceutical Sciences and Chemistry at the University of Wisconsin-Madison, holding the Janis Apinis Professorship in the School of Pharmacy and the Vilas Distinguished Achievement Professorship. He also serves as Director of the Medicinal Chemistry Center at the School of Pharmacy and maintains a faculty appointment with the Department of Chemistry in the College of Letters and Science. Janis Apinis Professor of Pharmaceutical Sciences Vilas Distinguished Achievement Professor Director of Medicinal Chemistry Center Faculty Appointment with Department of Chemistry Dr. Tang received his B.S. in Chemistry from Peking University in 1997, M.S. in Chemistry from New York University in 1999, Ph.D. in Organic Chemistry from Stanford University in 2005, and completed a postdoctoral fellowship in Medicinal Chemistry, Chemical Biology and Drug Discovery at Harvard University in 2007. Dr. Tang's research program focuses on drug discovery for cancer, infectious diseases, and neurodegenerative disorders through three interconnected areas: Organic Synthesis (advancing glycoscience through novel carbohydrate synthesis technologies), Medicinal Chemistry (developing small molecules that selectively remove disease-associated proteins), and Chemical Biology (dissecting biological pathways using novel small molecule probes). His group operates as an interdisciplinary team where chemists and biologists collaborate closely on drug discovery projects, with particular emphasis on developing novel degraders for disease-causing proteins. Analysis of Dr. Tang's publication record reveals a significant shift toward targeted protein degradation technologies, particularly PROTACs and molecular glues, while maintaining strong foundations in carbohydrate chemistry. His most impactful recent work includes developing degraders for extracellular and membrane proteins (previously considered 'undruggable'), creating rapid synthesis platforms like Rapid-TAC and Rapid-Glue, and advancing understanding of ternary complex formation for novel PROTAC design. His research spans both chemical methodology development and therapeutic applications across multiple disease areas. Vilas Distinguished Achievement Professorship Janis Apinis Professorship Numerous high-impact publications in leading chemistry and pharmacology journals Editor's pick and hot paper designations for significant contributions Dr. Tang mentors a diverse team of graduate students, postdoctoral fellows, and staff scientists with expertise spanning synthetic chemistry, medicinal chemistry, carbohydrate chemistry, computational chemistry, biochemistry, and cell biology. His group has developed innovative platforms for the rapid synthesis of protein degraders and has made significant contributions to understanding the mechanisms of action for these novel therapeutics. Current research includes developing selective degraders for cancer targets like RIPK1, BRD4, and CARM1, as well as advancing delivery systems for clinical translation. The Tang Research Group maintains state-of-the-art facilities within the School of Pharmacy at UW-Madison, equipped for comprehensive chemical synthesis, compound characterization, and biological evaluation. The group actively collaborates with researchers across campus and with industry partners to advance discoveries toward clinical applications, with particular focus on cancer therapeutics and protein degradation technologies.

• Targeted Protein Degradation
• PROTACs
• Medicinal Chemistry
• +۵ مورد دیگر

Wing Lam is an Associate Research Scientist in the Department of Pharmacology at the Yale School of Medicine. He holds a BSc in Molecular Biology and a PhD in Biochemical Pharmacology from City University of Hong Kong, followed by postdoctoral training at Yale. His research focuses on developing traditional Chinese medicine (TCM) formulations as adjuvants for cancer therapy, notably YIV-906, which enhances chemotherapy efficacy and mitigates intestinal toxicity. Lam also pioneered the STAR database for herbal drug discovery and the Mechanism-Based Quality Control (MBQC) platform for botanical drug standardization. Education: BSc (Hons) Molecular Biology, City University of Hong Kong, 1995 PhD Biochemical Pharmacology, City University of Hong Kong, 1999 Postdoc, Pharmacology, Yale University, 1999-2002 His research interests span cancer pharmacology, TCM modernization, and mitochondrial toxicity mechanisms. Key projects include YIV-906’s role in enhancing anti-PD1 and CAR T-cell therapies, developing L-nucleoside analogs like troxacitabine, and investigating tylophorine analogs’ antitumor effects. Lam has co-chaired sessions at multiple Consortium for Globalization of Chinese Medicine (CGCM) meetings and contributed to patents on herbal drug formulations and quality control methods. Recent work explores YIV-906’s potential for inflammatory bowel disease (IBD) and phase II clinical trials for colon and liver cancers. Lam’s publications highlight synergistic drug interactions, mitochondrial DNA depletion mechanisms, and TCM’s evidence-based application in chronic diseases. His grants include studies on PHY906 as an adjuvant in rectal cancer therapy and collaborations with Yiviva, Inc. He maintains active roles in editorial boards, including a special issue on herbal drug quality control in Frontiers in Pharmacology . Lam’s lab is embedded within Dr. Yung-Chi Cheng’s group, focusing on translational pharmacology and botanical drug innovation.

• Pharmacology
• Traditional Chinese Medicine
• Cancer Therapy
• +۷ مورد دیگر

Dr. Steven G. Clarke is a Distinguished Professor at UCLA Department of Chemistry & Biochemistry and director of research at the Molecular Biology Institute . His work bridges protein chemistry , methylation biology , and aging research through studies of spontaneous protein damage and its repair mechanisms. Education: BA in Chemistry and Zoology, Pomona College (magna cum laude, Phi Beta Kappa) PhD in Biochemistry and Molecular Biology, Harvard University (NSF Fellow) Postdoctoral Fellowship at UC Berkeley (Miller Fellow) Dr. Clarke's research focuses on protein isoaspartyl repair via PCMT1/PIMT enzymes , ribosomal protein methylation in Saccharomyces cerevisiae , and PRMT family characterization including PRMT7 and PRMT9. His lab combines biochemical assays , genetic models , and structural analysis to investigate aging mechanisms and disease implications. Recent publications highlight: COQ5 structure-function analysis in coenzyme Q biosynthesis PCMTD1 ubiquitin ligase interactions PRMT7 substrate specificity in histone H2B Protein isoaspartyl impacts on T cell function in lupus Novel PRMT inhibitors for cancer therapy Methionine addiction in osteosarcoma malignancy Major scientific awards: American Chemical Society Ralph F. Hirschmann Award in Peptide Chemistry NIH MERIT Award Ellison Medical Foundation Senior Scholar Award William C. Rose Award, ASBMB UCLA Distinguished Teaching Award (Eby Award winner) Current lab members include PhD candidates Eric Pang (UCSB) and Sining "Cindy" Wang (UCLA), while undergraduates Celeste Medina-Seymoure , Elizabeth Oroudjeva , Olivia Pacheco , and Jasmine Winter contribute to ongoing proteostasis studies. Collaborations with Profs. Jose Rodriguez and Catherine Clarke demonstrate interdisciplinary research approaches.

• Biochemistry
• Systems Biology
• Biological Regulation
• +۸ مورد دیگر

Chang-Jun Liu is a Senior Scientist in the Plant Science Group of the Biology Department at Brookhaven National Laboratory, where he has conducted research on plant phenylpropanoid biosynthesis and lignin metabolism since joining in 2005. He also holds an Adjunct Professor position in the Biochemistry & Cell Biology Department at Stony Brook University and serves as Associate Editor for Plant Cell & Environment (2024-present) and Frontiers in Plant Sciences (2015-present). Dr. Liu's educational background includes: Ph.D. in Plant Biochemistry and Molecular Biology from the Shanghai Institute of Plant Physiology, Chinese Academy of Science (1999) Dr. Liu's research integrates approaches from biochemistry, molecular genetics, biophysics, protein engineering, metabolic engineering, and synthetic biology to investigate phenylpropanoid and lignin biosynthesis in plants. His laboratory addresses fundamental questions about how lignin and related compounds are synthesized and incorporated into cell walls, how regulatory networks govern metabolic activity, and how lignification influences cell wall structure and function. A central aim of his research is optimizing plant feedstocks for efficient lignocellulosic biomass utilization. Analysis of Dr. Liu's publication record reveals a consistent trajectory from fundamental biochemical mechanisms to applied bioenergy solutions. His recent work focuses on cytochrome b5 diversity, electron transfer mechanisms in phenolic biosynthesis, and metabolic engineering approaches to modify lignin composition. This research spans from evolutionary studies of lignin biosynthesis across plant lineages to practical applications in bioenergy crop improvement. Dr. Liu has received recognition for his contributions to science, including: Brookhaven National Laboratory Science and Technology Award (2018) Dr. Liu serves as Editorial Board Member for the Journal of Biological Chemistry (2020-present), PNAS Nexus (2024-present), and Plant Physiology Journal (2025-). He is Scientific Lead at the Joint BioEnergy Institute, Feedstocks Division, Lawrence Berkeley National Laboratory, and Project Lead at the Center for Bioenergy Innovation, Oak Ridge National Laboratory. His research is funded by the U.S. Department of Energy through multiple Bioenergy Research Centers. Dr. Liu leads a research group at Brookhaven National Laboratory focused on elucidating the posttranslational regulation and macromolecular organization of lignin biosynthesis, with applications toward developing designer lignins and reducing biomass recalcitrance for sustainable biofuel production. His work addresses the critical challenge of lignin's dual nature: while it impedes enzymatic access to polysaccharides in biofuel production, it also represents the most abundant renewable source of aromatic carbon for high-value bioproducts.

• Phenylpropanoid biosynthesis
• Lignin biosynthesis and modification
• Plant cell wall structure
• +۷ مورد دیگر

Rotem Karni, PhD, is an Associate Professor of Genetics at the Perelman School of Medicine, University of Pennsylvania, Philadelphia. He leads a research lab focused on understanding how alternative RNA splicing contributes to cancer and genetic diseases, with a strong emphasis on translating these findings into RNA-based therapies. Karni's lab develops decoy oligonucleotides, small molecules, and splice-switching technologies to modulate splicing factors and enhance immunotherapy. Education BSc in Biological Chemistry from The Hebrew University of Jerusalem (1997) PhD in Biological Chemistry from The Hebrew University of Jerusalem, Israel (2002) Postdoctoral Fellowship at Cold Spring Harbor Laboratory, NY (2002-2007) Karni's research explores the deregulation of alternative splicing in oncogenesis, particularly how splicing factors like RBFOX2 and S6K1 influence metastasis, DNA repair, and immune checkpoint modulation. His team investigates m6A RNA modifications for stabilizing mutant genes, with applications in Duchenne Muscular Dystrophy and pancreatic cancer. The lab's work is commercialized through biotech companies: SKIP Therapeutics, Andlit Therapeutics, and RNAble. Selected Research Trends RNA mis-splicing and neoantigen generation (2025) Splicing factor inhibition for tumor suppression (2023) Metastatic splicing signatures in pancreatic cancer (2023) Immune checkpoint splicing in cancer immunotherapy (2021) m6A modulation for mRNA stabilization (2023) Advising & Collaborations Karni has mentored numerous PhD and postdoctoral researchers, many of whom now hold leadership roles in academia, biotech, and medical institutions globally. His lab collaborates extensively on projects involving RNA innovation, including partnerships with the Institute for RNA Innovation. Contact Department of Genetics & Institute for RNA Innovation, One uCity Square, Room 4018, Philadelphia, PA 19104 Phone: 215-898-5072 Email: Rotem.Karni@Upenn.edu

• Alternative RNA Splicing
• RNA Biology
• Cancer Therapy
• +۴ مورد دیگر

Sara Gallini is an Assistant Professor at EPFL, leading the Gallini Lab within the ISREC Department of the School of Engineering (SV). Her research focuses on understanding how healthy and oncogenic cells compete in skin epithelium, aiming to identify therapeutic targets for skin cancer prevention. She holds a Tenure Track position and teaches in the Life Sciences Engineering program. Her lab employs advanced in vivo imaging and single-cell analysis techniques. Education details are not explicitly provided, but her career includes a postdoctoral fellowship with the HFSP. Her research integrates molecular, cellular, and systems-level approaches to study cancer initiation and tissue homeostasis, particularly in injury-driven dynamics. Lab Members: Includes PhD student Mustafa Öztürk and technical staff Mélanie Sipion. Key Research Themes: Oncogenic cell competition, epidermal regeneration, EGFR/ERK signaling, and therapeutic target discovery. Her lab collaborates with clinical teams and uses models like mouse skin to study tumor suppression mechanisms. Future work aims to leverage healthy cell dynamics for cancer treatment strategies. Contact: SV 2527 office, +41216936764, sara.gallini@epfl.ch .

• Cancer Biology
• Cellular Dynamics
• Epithelial Biology
• +۳ مورد دیگر

Prof. Waldemar Kolanus leads the Molecular Immunology and Cell Biology department at the University of Bonn's Life & Medical Sciences Institute (LIMES) . His research bridges immunoregulation , stem cell dynamics , and metabolic stress responses in immune cells. Unit 2 member at LIMES Principal investigator in SFB 704 and ImmunoSensation Cluster Leads a multidisciplinary lab with postdocs, PhD students, and technical staff His work focuses on intracellular signaling pathways connecting immune activation to tissue homeostasis, particularly through: Cytohesin proteins in integrin-mediated adhesion and migration TRIM71 in stem cell regulation and congenital hydrocephalus High-salt environments affecting macrophage function Publication trends show expertise in immune cell migration , genetic models , and chemical inhibition , with frequent use of mice and zebrafish for in vivo studies. Key articles explore: TRIM71's dual role in auditory development and germ cell maintenance Cytohesin family's Golgi regulation and insulin signaling Ruxolitinib's off-target migration inhibition of dendritic cells Contact details: Address: LIMES Institute, Carl-Troll-Straße 31, Bonn Email: kolanus.sekretariat@uni-bonn.de Phone: +49 228 73-62788

• Molecular Immunology
• Cell Signaling
• Signal Transduction Pathways
• +۴ مورد دیگر

Dr. Michael Wilczek is Assistant Teaching Professor in Biotechnology/Bioinformatics at Northeastern University's Roux Institute. His research bridges virology, bioinformatics, and educational innovation, with particular focus on JC polyomavirus pathogenesis and graduate education reform. Key research domains include: Molecular mechanisms of viral infections Bioinformatic analysis of host-pathogen interactions Observational health and real-world evidence Evidence-based graduate education His publication record demonstrates: Expertise in JC polyomavirus cellular pathways Innovative applications of machine learning in virology High-throughput drug screening methodologies Health disparities research in aging populations

• Virology
• Bioinformatics
• Molecular Epidemiology
• +۳ مورد دیگر

Overview Sebastian Schuck is a Professor of Biochemistry and Molecular Cell Biology at Heidelberg University's Biochemistry Center (BZH). His research focuses on organelle homeostasis, particularly the endoplasmic reticulum (ER), with emphasis on ER membrane biogenesis, ER-phagy, and SHRED pathways. He leads an international team investigating how cells adapt ER structure and function under stress or disease conditions. Education & Career Since 2021: Professor at Heidelberg University BZH 2013–2021: Independent Group Leader at Heidelberg University's Center for Molecular Biology 2006–2013: Postdoc with Peter Walter at UCSF 2001–2006: PhD and Postdoc with Kai Simons at Dresden's Max Planck Institute 1995–2000: Biochemistry studies at Universities of Hannover and Tübingen Research Interests Dr. Schuck's lab explores molecular mechanisms underlying ER homeostasis, including: 1. ER expansion during stress via lipid synthesis 2. Microautophagy-mediated ER degradation via ESCRT machinery 3. SHRED pathway regulation of proteasomal degradation of misfolded proteins 4. Links between ER stress and neurodegenerative diseases/cancer Awards & Honors No specific awards listed, but recognized for pioneering contributions to understanding microautophagy and ER quality control mechanisms. Advising & Collaborations Advised over 20 PhD/Master's students and postdocs Collaborations with Carlos Bas-Orth (MPI Biochemistry), Liam Holt (NY), and others Labs & Teams Current lab includes 10+ members focusing on: - Human ER morphogenesis - Microautophagy dynamics - SHRED pathway mechanisms

• Cell Biology
• Molecular Biology
• Membrane Biology
• +۴ مورد دیگر